SpringWorks Therapeutics has completed enrollment for their phase 2b ReNeu trial evaluating mirdametinib, an investigational MEK inhibitor, in NF1 patients with plexiform neurofibromas.

A collaborative of specialists from around the globe has come together with a vision to help patients with pediatric Renovascular Hypertension (pRVH) get the best care possible. This diverse and comprehensive team of researchers, clinicians, patients and families will improve the quality of life and treatment outcomes for pRVH patients.

As we enter a new year, we reflect on your unwavering compassion and generosity. From the bottoms of our hearts, we thank you for your continued support of the NF Network and the thousands living with neurofibromatosis. Our work wouldn't be possible without you! See how we're making a difference together.

Mila was diagnosed with NF1 at 2 months old. At a one-year follow-up of a previously detected heart murmur, Mila was also diagnosed with Mid-Aortic Syndrome and Renovascular Stenosis - very rare manifestations of NF that caused Mila to have extremely high blood pressure. In her memory, her parents share Mila's story and raise awareness for NF1 and high blood pressure in infants and toddlers.